JP2006509766A - 神経障害性知覚喪失処置のための組成物およびその用途 - Google Patents
神経障害性知覚喪失処置のための組成物およびその用途 Download PDFInfo
- Publication number
- JP2006509766A JP2006509766A JP2004555767A JP2004555767A JP2006509766A JP 2006509766 A JP2006509766 A JP 2006509766A JP 2004555767 A JP2004555767 A JP 2004555767A JP 2004555767 A JP2004555767 A JP 2004555767A JP 2006509766 A JP2006509766 A JP 2006509766A
- Authority
- JP
- Japan
- Prior art keywords
- lidocaine
- nsp
- anesthetic
- neuropathic
- negative sensory
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000002981 neuropathic effect Effects 0.000 title claims description 17
- 206010040030 Sensory loss Diseases 0.000 title description 14
- 239000000203 mixture Substances 0.000 title description 12
- 238000011282 treatment Methods 0.000 title description 7
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 claims abstract description 42
- 229960004194 lidocaine Drugs 0.000 claims abstract description 42
- 238000000034 method Methods 0.000 claims abstract description 23
- 230000001953 sensory effect Effects 0.000 claims abstract description 16
- 208000024891 symptom Diseases 0.000 claims abstract description 15
- 230000003444 anaesthetic effect Effects 0.000 claims abstract description 13
- 206010033799 Paralysis Diseases 0.000 claims description 13
- 229920000728 polyester Polymers 0.000 claims description 11
- BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 claims description 8
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 claims description 6
- -1 phenokine Chemical compound 0.000 claims description 6
- 239000000853 adhesive Substances 0.000 claims description 5
- 230000001070 adhesive effect Effects 0.000 claims description 5
- 239000004745 nonwoven fabric Substances 0.000 claims description 5
- IOHPVZBSOKLVMN-UHFFFAOYSA-N 2-(2-phenylethyl)benzoic acid Chemical compound OC(=O)C1=CC=CC=C1CCC1=CC=CC=C1 IOHPVZBSOKLVMN-UHFFFAOYSA-N 0.000 claims description 4
- 239000004698 Polyethylene Substances 0.000 claims description 4
- 229920001328 Polyvinylidene chloride Polymers 0.000 claims description 4
- 229960005274 benzocaine Drugs 0.000 claims description 4
- 229920000573 polyethylene Polymers 0.000 claims description 4
- 229920000915 polyvinyl chloride Polymers 0.000 claims description 4
- 239000004800 polyvinyl chloride Substances 0.000 claims description 4
- 239000005033 polyvinylidene chloride Substances 0.000 claims description 4
- 229960004919 procaine Drugs 0.000 claims description 4
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 claims description 4
- 229920003051 synthetic elastomer Polymers 0.000 claims description 4
- 239000005061 synthetic rubber Substances 0.000 claims description 4
- 239000002759 woven fabric Substances 0.000 claims description 4
- LEBVLXFERQHONN-UHFFFAOYSA-N 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide Chemical compound CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C LEBVLXFERQHONN-UHFFFAOYSA-N 0.000 claims description 3
- VTUSIVBDOCDNHS-UHFFFAOYSA-N Etidocaine Chemical compound CCCN(CC)C(CC)C(=O)NC1=C(C)C=CC=C1C VTUSIVBDOCDNHS-UHFFFAOYSA-N 0.000 claims description 3
- KCLANYCVBBTKTO-UHFFFAOYSA-N Proparacaine Chemical compound CCCOC1=CC=C(C(=O)OCCN(CC)CC)C=C1N KCLANYCVBBTKTO-UHFFFAOYSA-N 0.000 claims description 3
- 229960003150 bupivacaine Drugs 0.000 claims description 3
- VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 claims description 3
- 229960002023 chloroprocaine Drugs 0.000 claims description 3
- 229960003920 cocaine Drugs 0.000 claims description 3
- 229960003976 etidocaine Drugs 0.000 claims description 3
- 229960002409 mepivacaine Drugs 0.000 claims description 3
- INWLQCZOYSRPNW-UHFFFAOYSA-N mepivacaine Chemical compound CN1CCCCC1C(=O)NC1=C(C)C=CC=C1C INWLQCZOYSRPNW-UHFFFAOYSA-N 0.000 claims description 3
- 229960001807 prilocaine Drugs 0.000 claims description 3
- MVFGUOIZUNYYSO-UHFFFAOYSA-N prilocaine Chemical compound CCCNC(C)C(=O)NC1=CC=CC=C1C MVFGUOIZUNYYSO-UHFFFAOYSA-N 0.000 claims description 3
- 229960003981 proparacaine Drugs 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- 229960002372 tetracaine Drugs 0.000 claims description 3
- GKCBAIGFKIBETG-UHFFFAOYSA-N tetracaine Chemical compound CCCCNC1=CC=C(C(=O)OCCN(C)C)C=C1 GKCBAIGFKIBETG-UHFFFAOYSA-N 0.000 claims description 3
- CAJIGINSTLKQMM-UHFFFAOYSA-N Propoxycaine Chemical compound CCCOC1=CC(N)=CC=C1C(=O)OCCN(CC)CC CAJIGINSTLKQMM-UHFFFAOYSA-N 0.000 claims description 2
- 229960001747 cinchocaine Drugs 0.000 claims description 2
- PUFQVTATUTYEAL-UHFFFAOYSA-N cinchocaine Chemical compound C1=CC=CC2=NC(OCCCC)=CC(C(=O)NCCN(CC)CC)=C21 PUFQVTATUTYEAL-UHFFFAOYSA-N 0.000 claims description 2
- 238000002690 local anesthesia Methods 0.000 claims description 2
- 239000000463 material Substances 0.000 claims description 2
- 229950003255 propoxycaine Drugs 0.000 claims description 2
- 208000002193 Pain Diseases 0.000 abstract description 15
- 229940035674 anesthetics Drugs 0.000 abstract description 12
- 239000003193 general anesthetic agent Substances 0.000 abstract description 12
- 230000036407 pain Effects 0.000 abstract description 11
- 208000033808 peripheral neuropathy Diseases 0.000 abstract description 10
- 201000001119 neuropathy Diseases 0.000 abstract description 9
- 230000007823 neuropathy Effects 0.000 abstract description 9
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 abstract description 6
- 230000000694 effects Effects 0.000 abstract description 4
- 239000005711 Benzoic acid Substances 0.000 abstract description 3
- 235000010233 benzoic acid Nutrition 0.000 abstract description 3
- 230000009023 proprioceptive sensation Effects 0.000 abstract description 3
- 235000019633 pungent taste Nutrition 0.000 abstract description 2
- 239000003589 local anesthetic agent Substances 0.000 description 9
- 230000035807 sensation Effects 0.000 description 7
- 235000019615 sensations Nutrition 0.000 description 7
- 239000004480 active ingredient Substances 0.000 description 6
- 208000004044 Hypesthesia Diseases 0.000 description 4
- 150000001408 amides Chemical class 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 210000000578 peripheral nerve Anatomy 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 229960005015 local anesthetics Drugs 0.000 description 3
- 210000005036 nerve Anatomy 0.000 description 3
- 239000011505 plaster Substances 0.000 description 3
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 2
- 241000086254 Arnica montana Species 0.000 description 2
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 208000012902 Nervous system disease Diseases 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- 208000004296 neuralgia Diseases 0.000 description 2
- 208000021722 neuropathic pain Diseases 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 239000003195 sodium channel blocking agent Substances 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 230000036410 touch Effects 0.000 description 2
- 230000037317 transdermal delivery Effects 0.000 description 2
- GTQXPCWVIUCJCK-UHFFFAOYSA-N 2-(diethylamino)ethyl 4-aminobenzoate;oxoborinic acid Chemical compound OB=O.OB=O.OB=O.OB=O.OB=O.CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 GTQXPCWVIUCJCK-UHFFFAOYSA-N 0.000 description 1
- XFDUHJPVQKIXHO-UHFFFAOYSA-N 3-aminobenzoic acid Chemical compound NC1=CC=CC(C(O)=O)=C1 XFDUHJPVQKIXHO-UHFFFAOYSA-N 0.000 description 1
- 208000000094 Chronic Pain Diseases 0.000 description 1
- GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 208000028389 Nerve injury Diseases 0.000 description 1
- 206010040021 Sensory abnormalities Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000003416 antiarrhythmic agent Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- JJCJKGKSHRXGHT-UHFFFAOYSA-N butanoic acid;2-(diethylamino)ethyl 4-aminobenzoate Chemical compound CCCC(O)=O.CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 JJCJKGKSHRXGHT-UHFFFAOYSA-N 0.000 description 1
- 229960002896 clonidine Drugs 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 229960002870 gabapentin Drugs 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000008764 nerve damage Effects 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 208000035824 paresthesia Diseases 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- AYXYPKUFHZROOJ-ZETCQYMHSA-N pregabalin Chemical compound CC(C)C[C@H](CN)CC(O)=O AYXYPKUFHZROOJ-ZETCQYMHSA-N 0.000 description 1
- 229960001233 pregabalin Drugs 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000002889 sympathetic effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
- A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
- A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Anesthesiology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US42920802P | 2002-11-26 | 2002-11-26 | |
| PCT/US2003/037815 WO2004047819A2 (en) | 2002-11-26 | 2003-11-25 | Composition and its use for treating neuropathic sensory loss |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006509766A true JP2006509766A (ja) | 2006-03-23 |
| JP2006509766A5 JP2006509766A5 (enExample) | 2007-01-11 |
Family
ID=32393523
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004555767A Pending JP2006509766A (ja) | 2002-11-26 | 2003-11-25 | 神経障害性知覚喪失処置のための組成物およびその用途 |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP1565173B1 (enExample) |
| JP (1) | JP2006509766A (enExample) |
| CN (1) | CN1717229A (enExample) |
| AT (1) | ATE420633T1 (enExample) |
| AU (1) | AU2003298710B2 (enExample) |
| CA (1) | CA2507217C (enExample) |
| DE (1) | DE60325885D1 (enExample) |
| ES (1) | ES2319764T3 (enExample) |
| WO (1) | WO2004047819A2 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7718674B2 (en) | 2004-09-27 | 2010-05-18 | Bridge Pharma, Inc. | Methods of relieving neuropathic pain with the S-isomer of 2-{2[N-(2-indanyl)-N-phenylamino]ethyl}piperidine |
| US7592458B2 (en) | 2006-07-21 | 2009-09-22 | Wright George E | Dermal anesthetic compounds and pharmaceutical compositions for inducing local anesthesia and mitigating neuropathic pain |
| CA2732784C (en) * | 2008-08-13 | 2018-09-18 | Neuroquest Inc. | Compositions comprising terpene compounds for treating negative sensory phenomena |
| CA2738524C (en) | 2008-10-02 | 2013-11-26 | Mylan Inc. | Method for making a multilayer adhesive laminate |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH06508820A (ja) * | 1991-02-27 | 1994-10-06 | ノーヴェン ファーマシューティカルズ インコーポレイテッド | 医薬活性剤の局所投与用組成物及び局所投与方法 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5993018A (ja) * | 1982-11-18 | 1984-05-29 | Sumitomo Chem Co Ltd | 顔面錯感覚症治療薬 |
-
2003
- 2003-11-25 ES ES03796465T patent/ES2319764T3/es not_active Expired - Lifetime
- 2003-11-25 WO PCT/US2003/037815 patent/WO2004047819A2/en not_active Ceased
- 2003-11-25 JP JP2004555767A patent/JP2006509766A/ja active Pending
- 2003-11-25 CA CA2507217A patent/CA2507217C/en not_active Expired - Fee Related
- 2003-11-25 AU AU2003298710A patent/AU2003298710B2/en not_active Ceased
- 2003-11-25 EP EP03796465A patent/EP1565173B1/en not_active Expired - Lifetime
- 2003-11-25 AT AT03796465T patent/ATE420633T1/de not_active IP Right Cessation
- 2003-11-25 DE DE60325885T patent/DE60325885D1/de not_active Expired - Lifetime
- 2003-11-25 CN CNA2003801041719A patent/CN1717229A/zh active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH06508820A (ja) * | 1991-02-27 | 1994-10-06 | ノーヴェン ファーマシューティカルズ インコーポレイテッド | 医薬活性剤の局所投与用組成物及び局所投与方法 |
Non-Patent Citations (1)
| Title |
|---|
| JPN5005011765, ＴＨＥ ＣＬＩＮＩＣＡＬ ＪＯＵＲＮＡＬ ＯＦ ＰＡＩＮ, 2000, １６，３, ２０５−２０８ * |
Also Published As
| Publication number | Publication date |
|---|---|
| ATE420633T1 (de) | 2009-01-15 |
| DE60325885D1 (de) | 2009-03-05 |
| CA2507217A1 (en) | 2004-06-10 |
| AU2003298710B2 (en) | 2008-02-07 |
| WO2004047819A2 (en) | 2004-06-10 |
| EP1565173A2 (en) | 2005-08-24 |
| WO2004047819A3 (en) | 2004-07-29 |
| EP1565173B1 (en) | 2009-01-14 |
| CA2507217C (en) | 2012-08-28 |
| ES2319764T3 (es) | 2009-05-12 |
| CN1717229A (zh) | 2006-01-04 |
| AU2003298710A1 (en) | 2004-06-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1571656B (zh) | 利多卡因在制备用于治疗非神经病性疼痛的透皮贴剂中的用途 | |
| AU2005251740B2 (en) | Preparation for localized delivery of therapeutic agent | |
| JP5148271B2 (ja) | 疼痛処置のためのカプサイシノイド、局所麻酔薬および／または鎮痒薬を含有する処方物 | |
| EP0506658B1 (en) | Compositions and method for treating painful, inflammatory or allergic disorders | |
| WO2004039325A3 (en) | Treatment of pain with jnk inhibitors | |
| JP6196704B2 (ja) | 神経因性疾病の治療のための医薬 | |
| Altman et al. | Local anesthetics | |
| Pappagallo et al. | Pharmacological management of postherpetic neuralgia | |
| CA1169774A (en) | Medication having penetration through cutaneous surfaces into articular and muscular areas | |
| CA2507217C (en) | Compositions and methods for treating neuropathic sensory loss | |
| US20050112183A1 (en) | Compositions and methods for treating neuropathic sensory loss | |
| EP1318801B1 (en) | Topical analgesic compositions containing aliphatic polyamines and methods of using same | |
| Agarwal et al. | Comparative evaluation of Myolaxin and EM LA cream for attenuation of venous cannulation pain: A prospective, randomised, double blind study | |
| US20190365730A1 (en) | Anaesthetic composition comprising ropivacaine, prilocaine and lidocaine | |
| Brown et al. | Treatment of pediatric chronic pain with tramadol hydrochloride: Siblings with Ehlers‐Danlos syndrome‐hypermobility type | |
| Kramer et al. | Overview of Local Anesthesia | |
| US11813237B2 (en) | Creatine, its derivatives, compositions and methods of use thereof | |
| JPH061721A (ja) | 疼痛処置剤、及び疼痛軽減作用増強剤 | |
| ES2963708T3 (es) | Bromhexina para el tratamiento del dolor | |
| JP2006298934A (ja) | 局所的局所麻酔薬組成物を用いる頭痛の痛みを処置するための方法 | |
| JPS5993018A (ja) | 顔面錯感覚症治療薬 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20061116 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20061116 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100520 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20100830 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20101209 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20110117 |
|
| A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20110204 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20120425 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20120501 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20120523 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20120528 |